Nanox is a nano-biotechnology company, constantly engaged in the research and development of advanced discovery, testing and commercialization of nano-pharmaceutical drugs. The company has developed and specialized in conventional liposomes, pegylated liposomes, and microspheres depot with PLGA (polylactide - polyglycolide copolymers) formulations. These technologies are applicable to drugs, small molecules, peptides and proteins. Nanox's current activities have focused on the clinical development of nano-particulate targeting of drug to specific tissues with promise of progressive treatment and innovative therapeutics options with high efficacy and less side effects for patients with high unmet medical needs. As a fully integrated nanotechnology company, Nanox delivers innovative nanotech solutions, across discovery and development.
The company's core business focuses in the development and innovation of alternative nanotech drug delivery processes and products destined to complex treatments such as oncology, hematology, transplants, infections and AIDS. In addition, Nanox provides advanced drug formulation, products development, clinical scale manufacturing and technical support to the pharmaceutical industry worldwide with a focus on difficult-to-formulate active pharmaceutical ingredients. We seek to deliver truly innovative and life-changing drugs. Our mission as a company is to build a major global nano-biopharmaceutical corporation while focusing on the discovery, the nano-technology, the development, and the commercialization of products for the treatment of the cancer and other severe immune, inflammatory conditions.
Our Mission as a company is to build a major global nano-biopharmaceutical corporation while focusing on the discovery, the Nano- technology, the development, and the commercialization of products for the treatment of the cancer and other severe immune, inflammatory conditions.
Liposomes are vesicular sacs similar to tiny cells, composed by durable lipid bilayer membranes that separate an internal aqueous volume from the external meduim.
The pegylation of proteins was developed for improving biomedical efficacy, physicochemical and pharmacokinetics properties, and to reduce the number of weekly injections used in the treatment.
The delivery of controlled release drug employs drug-encapsulating devices from which therapeutic agents may be released at controlled rates for long periods of time.
This novel technology encapsulates different drugs within Nanomicells formed with Gangliosides GM1. Triple enhanced mechanism of action. Direct uptake of the nanomicell by the tumor cell. The nanomicell diffuses from the bloodstream to the tumor microenvironment and there is taken up by the cell, acting during the cell division resulting in slowing tumor growth.
The patent for an oncology scientific development carried out by Ceprocor was transferred to the company Nanox Realese Technology. From now on, the company and researchers (...)
It is a nanostructure developed and transferred by CEPROCOR and CONICET capable of transporting cancer drugs to tumor cells. In the next phase, Nanox will advance in clinical (...)
For the treatment of glioma and other central nervous system diseases, one of the biggest challenges is that most therapeutic drugs cannot be delivered to the brain tumor tissue due to the blood–brain barrier (BBB) (...)